Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE

Rosa Divella, Antonella Daniele, Ines Abbate, Eufemia Savino, Porzia Casamassima, Giancarlo Sciortino, Giovanni Simone, Gennaro Gadaleta-Caldarola, Vito Fazio, Cosimo Damiano Gadaleta, Carlo Sabbà, Antonio Mazzocca

Research output: Contribution to journalArticle


Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism as a potential predictive factor of poor prognosis in HCC patients treated with transcatheter arterial chemoembolization (TACE). In particular,we showthat the guanosine insertion/deletion polymorphismin the promoter region of SERPINE1 gene at the−675 bp position, named 4G/4G, predicts poor prognosis in a cohort of 75 patientswith HCC undergoing TACE. By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE. Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treatedwith TACE. In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

Original languageEnglish
Pages (from-to)273-278
Number of pages6
JournalTranslational Oncology
Issue number4
Publication statusPublished - Aug 1 2015


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this